biotech / news / / USA TODAY
Eli Lilly says its experimental weight-loss shot retatrutide delivered dramatic weight loss in a late-stage study of people with obesity.
Eli Lilly's retatrutide weight-loss shot achieved up to 28% weight loss in late-stage trials.
KEY POINTS
- Nearly half of participants on the highest dose lost over 30% of body weight, matching surgery outcomes.
- Retatrutide combines GIP, GLP-1, and glucagon receptor agonists, unlike current GLP-1-only drugs.
- Lilly has not yet filed for FDA approval but may do so before the end of this year.
COMPANIES
Summarized by Newsio from USA TODAY. How we summarize →